Regenerex Pharma, Inc. Auditor Resignation — dbbmckennon Ends Services

What Happened
Regenerex Pharma, Inc. filed an 8-K on September 4, 2026 reporting that its independent registered public accounting firm, dbbmckennon, notified the company it would cease providing audit services effective August 31, 2026. dbbmckennon had served as Regenerex’s auditor since 2017. The auditor’s reports on the Company’s financial statements for the fiscal years ended December 31, 2025 and March 31, 2025 did not contain adverse opinions or disclaimers, but did include an explanatory paragraph noting substantial doubt about the Company’s ability to continue as a going concern. The transition-period report (Apr 1, 2025 to Dec 31, 2025) also included an explanatory paragraph about a revision disclosing certain related-party transactions.

Key Details

• Resignation date: dbbmckennon ceased services effective August 31, 2026; 8-K filed September 4, 2026.
• Auditor tenure: dbbmckennon served as Regenerex’s independent auditor since 2017.
• Audit report notes: Reports for year-ends Dec 31, 2025 and Mar 31, 2025 included an explanatory “going concern” paragraph; transition period report disclosed a revision for related-party transactions.
• No disagreements or “reportable events” were identified between the company and dbbmckennon for the two most recent fiscal years. The company is in the process of engaging a successor auditor and will file dbbmckennon’s letter to the SEC as Exhibit 16.1.

Why It Matters
A change in independent auditor is material for investors because it can affect the timing and completion of audited financial statements and the company’s ability to timely file SEC reports. The filing confirms the auditor flagged substantial doubt about Regenerex’s ability to continue as a going concern in recent audit reports, which is important context for assessing financial health. The company states it is actively seeking a successor auditor and working to bring its periodic filings current — investors should watch for the appointment of the new auditor and any updates to the company’s audited financial statements or filing status.